Canadian Researchers Identify Hidden Brain Cell Communication Powering Aggressive Glioblastoma Tumor Growth

McMaster scientists discover brain cells help glioblastoma grow, suggesting an existing HIV drug could be repurposed to block this deadly communication.

By: AXL Media

Published: Apr 6, 2026, 9:10 AM EDT

Source: Information for this report was sourced from ScienceDaily

A Molecular Betrayal Within the Neural Ecosystem

The traditional view of glioblastoma as a localized cluster of rogue cells is being replaced by a more complex understanding of a cooperative biological environment. According to Sheila Singh, a professor of surgery at McMaster University, the disease functions as an intricate ecosystem where cancer cells do not act in isolation. New data reveals that the surrounding brain environment is not merely a passive victim of the tumor but is frequently co-opted into supporting its survival. This shift in perspective has allowed researchers to pinpoint specific interactions that, if severed, could fundamentally compromise the tumor's ability to maintain its aggressive pace of expansion.

The Transformation of Protective Support Cells

Central to this discovery are oligodendrocytes, cells primarily responsible for the insulation and protection of healthy nerve fibers. The study indicates that these cells undergo a behavioral shift in the presence of a tumor, transitioning from their supportive roles to becoming active participants in the cancer’s growth. By establishing a defined signaling system, these reactive oligodendrocytes create a fertile environment for the tumor to expand. When the research team successfully interrupted this specific communication channel in laboratory models, the results were immediate, the rate of tumor growth decreased significantly, confirming the dependency of the cancer on these external signals.

Repurposing Antiviral Medication for Oncology

The identification of the CCR5 receptor as a primary driver of this cellular dialogue has led to an unexpected therapeutic lead. Researchers noted that this specific receptor is already a known target of Maraviroc, a drug currently utilized in the management of HIV. Because this medication has already cleared the rigorous safety and regulatory hurdles required for public use, it represents a significantly faster route to clinical application than a newly developed compound. Jason Moffat, a senior scientist at SickKids, emphasized that uncovering this piece of biology allows for the immediate exploration of whether blocking this pathway can accelerate the delivery of new treatment options to patients with few alternatives.